Bagodilol 6,25

Kraj: Armenia

Język: angielski

Źródło: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Składnik aktywny:

carvedilol

Dostępny od:

Laboratorios Bago S.A.

INN (International Nazwa):

carvedilol

Dawkowanie:

6,25mg

Forma farmaceutyczna:

tablets

Typ recepty:

Prescription

Charakterystyka produktu

BAGODILOL
CARVEDILOL
TABLETS
SUMMARY OF PRODUCT CHARACTERISTICS
PROPRIETARY
NAME
BAGODILOL 3.125
BAGODILOL 6.25
BAGODILOL 12.5
BAGODILOL 25
INTERNATIONAL
NONPROPRIETARY
NAME
(INN)
Carvedilol
CHEMICAL
NAME
(
±
)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol.
Carvedilol
is
a
racemic
mixture
with
the
following
structure:
Molecular
weight:
406.5
DOSAGE
FORM
Tablets
ROUTE
OF
ADMINISTRATION
Oral
COMPOSITION
BAGODILOL
3.125:
Each
tablet
contains:
Carvedilol
3.125
mg
_Inactive_
_ _
_ingredients_
:
Colloidal
Anhydrous
Silica,
Magnesium
Stearate,
Povidone,
Sodium
Starch
Glycolate,
Sucrose,
Ferric
Oxide,
Mycrocrystalline
cellulose.
Contains
10.75
mg
of
Sucrose.
BAGODILOL
CARVEDILOL
TABLETS
BAGODILOL
6.25:
Each
tablet
contains:
Carvedilol
6.25
mg
_Inactive_
_ _
_ingredients_
:
Colloidal
Anhydrous
Silica,
Magnesium
Stearate,
Povidone,
Sodium
Starch
Glycolate,
Sucrose,
Mycrocrystalline
cellulose.
Contains
10.75
mg
of
Sucrose.
BAGODILOL
12.5:
Each
tablet
contains:
Carvedilol
12.5
mg
_Inactive_
_ _
_ingredients_
:
Colloidal
Anhydrous
Silica,
Magnesium
Stearate,
Povidone,
Sodium
Starch
Glycolate,
Sucrose,
Mycrocrystalline
cellulose.
Contains
21.5
mg
of
Sucrose.
B
AGODILOL
25:
Each
tablet
contains:
Carvedilol
25
mg
_Inactive_
_ _
_ingredients_
:
Colloidal
Anhydrous
Silica,
Magnesium
Stearate,
Povidone,
Sodium
Starch
Glycolate,
Sucrose,
Mycrocrystalline
cellulose.
Contains
43
mg
of
Sucrose.
CLINICAL
CHARACTERISTICS
T
HERAPEUTIC
ACTION
Antihypertensive
agent.
Treatment
of
stable
angina
pectoris.
Treatment
of
congestive
heart
failure
(NYHA:
class
II-III).
I
NDICATIONS
Essential
hypertension.
Stable
angina
pectoris.
Congestive
heart
failure
(NYHA:
class
II-III).
D
OSAGE
AND
ADMINISTRATION
Doses
will
be
adjusted
according
to
medical
criterion,
to
the
clinical
status
of
the
patient.
It
is
recommended
that:
ESSENTIAL
HYPERTENSION
/
ANGINA
PECTORIS:
_ADULTS:_
The
recommended
initial
dose
is
12.5
mg/day
for
the
first
two
days
increasing
up
to
25
mg/day
in
a
single
daily
intake.
This
dosage
is
enough
for
most
of
the